Neil Blumberg: Clinical Harm Associated With Infusion of ABO Incompatible Antibody and Antigen
Neil Blumberg, Transfusion Medicine Specialist and Platelet Researcher (Former Professor and Director, URMC), shared on LinkedIn:
“Some ideas become dogma without any strong data to support them. Examples include the equivalent safety of universal donor group O red cells and group AB plasma to ABO identical transfusions. Data have now accumulated to show that these assumptions are largely incorrect.
Our group reviewed the data demonstrating that infusion of modest amounts of ABO incompatible cellular and soluble antigen, and ABO incompatible plasma are associated with clinical harm, including increased mortality.
Tong N, Masel D, Nguyen PL, Asante A, Refaai M, Heal JM, Blumberg N.
The case against infusing ABO incompatible antibody and antigen from all blood components.
Transfus Apher Sci. 2026 Jan 31;65(2):104402. doi: 10.1016/j.transci.2026.104402. Epub ahead of print. PMID: 41633302.
Abstract
The transfusion of ABO compatible but not ABO identical red blood cells and plasma and the transfusion of platelets and cryoprecipitate without concern for ABO in any manner, are practices that have been accepted as safe for patients.
While these practices make managing blood component inventories easier by reducing component outdating, they do lead to the development of immune complexes, donor antibody induced hemolysis, and potentially endothelial cell and platelet injury.
A growing body of evidence has shown that these practices are associated, likely causally, with negative consequences for patients including increased mortality.
The adoption of a policy of providing only ABO identical blood components when practical, and avoiding infusion of ABO incompatible antibody, cellular and soluble antigen should thus become the optimal standard of care for patients.
For those without access to the full article, request a .pdf from [email protected].”
Find more posts featuring Neil Blumberg on Hemostasis Today.
-
May 12, 2026, 16:46Tagreed Alkaltham: Why Apheresis Matters in Modern Transfusion Medicine
-
May 12, 2026, 16:37Reinhold Kreutz: Cardiovascular Burden in Acute Intermittent Porphyria Needs Greater Awareness
-
May 12, 2026, 16:33Pablo Corral: The Truth About Very Low LDL-Cholesterol
-
May 12, 2026, 16:24Mildred Lundgren: We Must Talk About the Invisible Causes of Stroke
-
May 12, 2026, 16:17Irene Scala: The Sex Disparities In Access to Acute Stroke Treatments In Italy
-
May 12, 2026, 16:04May Nour: UCLA Health Mobile Stroke Unit Becomes The 1st In The World to Perform mCTA In the Field
-
May 12, 2026, 15:57Leonardo Roever: Prognostic Impact of Lipoprotein(a) and CAR in Elderly Acute Ischemic Stroke Patients
-
May 12, 2026, 15:54Bruno Pougault: Prioritizing Laboratory Tests in Resource-Limited Emergency Care
-
May 12, 2026, 15:37Jennifer Holter Chakrabarty: Supporting the Next Generation of Hematology Researchers